CBER Oncology Group Will Work To Create Consistent Approach To Products
Executive Summary
The Office of Cellular, Gene & Tissue Therapies' new oncology group will work to ensure coordination in approaches to oncology products throughout FDA
You may also be interested in...
FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
FDA oncologic gene and cellular therapies
FDA Division of Oncologic Drug Products Medical Officer Steven Hirschfeld, MD/PhD, will become Oncology Group Leader in the Office of Cellular, Gene & Tissue Therapies in the Center for Biologics Evaluation & Research. Hirschfeld assumes the position starting Nov. 3...